Versant Launches Inception IBD, A New Company With Old Roots
This article was originally published in Start Up
Executive Summary
Versant and Celgene have partnered again to launch a build-to-buy biotech, this time focusing on inflammatory bowel disease.
You may also be interested in...
Here To Stay: Inception Sciences Shows Why Build-To-Buy Works
Born at a time when venture capital found few exit opportunities for early-stage companies, build-to-buy helped mitigate the risk in investing in uncharted science. But the model is flourishing even in this period of wider capital options.
Deal Watch: Pfizer, BioAtla Team Up To Develop Targeted Antibody Oncologics
ViroMed looks to bluebird to take its humanized antibody to the next steps of development in immuno-oncology. Takeda gets option for Cour's nanoparticle technology in Celiac disease, as well as up to three other indications.
Versant Continues “Build-To-Buy” With New Fund
Versant Ventures joined the ranks of venture capital firms closing new funds recently, thanks in part to the swell in biotech initial public offerings this year. Versant’s Fund V represents an oversubscribed level of approximately $55 million to its intended $250 million target.